Carter Jaynes, radioligand therapy (RLT) production manager at Novartis, at work in the company’s *10,000-square-foot radioligand therapy (RLT) manufacturing facility…
Novartis is paying $105 million upfront to task Antares Therapeutics with generating small molecules against historically undruggable oncology targets. Antares…